Lyell Immunopharma Goldman Sachs’ RxChange Series: Framing Lyell’s next-generation lymphoma CAR-T data in 4Q
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
on the firm portals. Disclosures and updates to disclosures are also available by ticker on the firm's public website. With that, I am very pleased to start today's call here. We are pleased to have both Dr. Lynn Seely, who is President and CEO of Lyell, as well as Dr. Alexander Boardman, Associate Physician, Division of Hematology/Oncology at Mass General Brigham Cancer Institute, and Faculty of Medicine at Harvard Medical School. I am joined by my colleague, Mark Elenick. To start here, Lynn, could you provide us a high-level overview of where your lead program stands, the autologous CD19/CD20 CAR T, ronde-cel, across the studies in B-cell lymphoma? Maybe start by touching upon the data that was released yesterday via the ASH abstracts as well.
Sure. Selvine, thanks for having Lyell here today. For those who are not as familiar with Lyell, we are a late-stage clinical cell therapy company. We are developing next-generation CAR T-cell therapies for patients both with hematologic malignancies and solid tumors, cancers. Today, we are here to talk about ronde-cel, which is our lead program. As Selvine alluded to, it is a CD19/CD20 dual-targeting CAR T-cell therapy, which is very specifically designed to be full potency at either CD19 or CD20. It is manufactured very specifically to have a predominance of naive T-cells in the cell product through a very special process called CD62L enrichment. The goal of this is really to drive more complete responses, longer duration of response, better CAR T-cell persistence, all with a softer safety profile. That was sort of really the design of the product.
I am pleased to say, as Selvine just mentioned, yesterday, ASH abstracts were released, and ronde-cel will be presented in two presentations at ASH. Our ongoing pivotal PiNACLE trial, which I will speak about in a moment, will have a significant data update where we are showing again these high durable complete response rates, exactly as the product profile was designed to achieve. That will be in an oral presentation. We will also be having a poster presentation on a second-line cohort that we are running, and this is from a phase I/II multi-cohort trial. At this point in time, ronde-cel is in evaluation in two pivotal trials. We are completing enrollment in the PiNACLE trial, which is a third or later line single-arm trial, which is designed to gain us approval. We will be having the full pivotal data set mid-next year with a BLA submission to follow soon thereafter.
This is a very exciting trial for us, and we believe will lead us to be the first approved CD19/CD20 CAR T-cell therapy program. We also have ongoing and enrolling right now the first of its kind, a randomized controlled phase III trial head-to-head, our CAR T-cell therapy, ronde-cel, versus investigator's choice of either axi-cel or liso-cel. This is a very exciting program that we have designed based on the very strong data that we are seeing in the clinic to date. I will look forward to diving in a little bit more detail. I would last just close my opening remarks with this, something that Lyell is really unique about, is we have our own manufacturing center, and we can make more than 3,000 CAR T-cell doses per year from that center at full capacity.
We are running our commercial manufacturing process as we speak. I am proud to say we have a 98% success rate delivering product to patient with a median vein-to-site time, which is quite competitive at 16 days. We are really looking forward to commercializing ronde-cel if this product gets approved.
Great. Dr. Boardman, before we get into the data here, could you briefly discuss your background and clinical practice and how many lymphoma patients you see annually? How many receive CAR T in the second line or third line plus settings?
Absolutely. Thank you so much for the introduction and for inviting me to speak. In brief, I did most of my early training in the Boston area. I did my internal medicine residency training at Brigham and Women's Hospital and Harvard Medical School. I then went down to New York City for my hematology oncology training at Memorial Sloan Kettering Cancer Center. As a fellow there, I led preclinical research that was aimed at understanding the molecular underpinnings of CAR T-cell toxicity, including cytokine release syndrome. I also took an early clinical interest in treating cell therapy patients. I went on to become an attending physician there, and I led early phase clinical trials in cell therapy, as well as translational research.
To get to your question, in terms of my clinical breakdown, I specialized in treating only lymphoma. Also, about 25% of my clinical time was treating patients with CAR T-cells. That amounted to treating about 20 patients per year with a CD19 CAR T-cell product. In total, I had amounted a panel of about 500 patients that probably translated to something like 1,500 visits per year. I would say about 20% or so of those patients were on active treatment. As you can tell from my introduction, I am transitioning my practice to Mass General Brigham as we speak, and I look forward to taking on a very similar clinical footprint in Boston.
Great. To start here on the data side, let's chat about the third line plus large B-cell lymphoma market. Updated phase I/II data for ronde-cel in both the second line and third line settings will be presented at ASH. Just looking at the emerging clinical profile in the third line setting or third line plus setting, ronde-cel achieved a 91% ORR and a 77% complete response rate, with 75% remaining at CR at 12 months. Dr. Boardman, can you contextualize these response rates against existing standard of care for the autologous CD19 CAR-Ts, and also the bispecifics in later line settings?
Yeah, absolutely. I always preface these comments by admitting to the caveats of comparing studies to each other. Obviously, these are studies that have differences in eligibility criteria and baseline characteristics. To speak about, firstly, about third line CAR-T in terms of the commercial products, I will really focus on BREYANZI and YESCARTA because those are really the products that are predominantly being prescribed by U.S. providers, relative to KYMRIAH, which really has, at the very least in real-world data, shown to be a less effective product. But in thinking about YESCARTA and BREYANZI in the third line, usually we are looking at overall response rates ranging from 70%-80%, something like that. Compared to the 91% we are seeing in the Lyell study, that is very impressive. CR rates tend to be 50%-60% or so. Again, these are very high response rates relative to those.
In thinking about third line bispecifics, on the basis of the fact that bispecifics are coming to the market later than CAR-T, the way in which they were studied has to be taken in that context, right? Over 10% of patients in the pivotal studies leading to approvals of glofitamab and epcoritamab were CD19 CAR T-cell exposed patients, and they were heavily pre-treated. But with that in mind, the overall response rates were about 10%-20% lower in those pivotal studies. For instance, glofitamab and epcoritamab, we typically see somewhere in the range of 50%-60% overall response, and then CR rates in the range of 40% or so. Certainly lower than we were seeing in the pivotal phase III CD19 CAR T-cell studies, and substantially lower than what we are observing with the Lyell data.
In terms of speaking to the percent remaining in CR, I think you have to take that in the context of, first of all, how many patients are getting into CR, right? We are seeing almost 80% of patients getting into CR, and three-quarters of those remain in CR at 12 months. To compare that to the third line commercial CD19 CAR T-cell products, with the lower CR rates, generally about 65%-70% or so, a bit lower remaining in CR at that 12-month mark. This is very impressive, and I think that will bear watching as the follow-up matures.
Right. Maybe we can talk about that maturity with regard to durability here, but median PFS was not reached, noting an estimated 54% 24-month PFS rate. In your practice, what threshold of durability will represent a truly differentiated clinical outcome rather than an incremental benefit?
Yeah. To put this into context a little bit, we know that the vast majority of relapses are occurring in the first six months for these patients. When I have a patient who comes to clinic who's in a CR at one year, I usually tell them they have a less than 10% chance of relapsing. At two years, it's even lower, so probably less than 5%. In the CAR T-cell studies with the longest follow-up, we have seen relapses from large cell lymphoma as late as five years, but it's exceedingly uncommon.
What we're looking at for the benchmark for something like a 24-month PFS, which is a reasonable surrogate for patients that we're curing, is about 30%-40%, which is, in the third line, is typically what we expect, what we generally quote as probably the percent of patients that we're curing in the third line or greater with CAR T-cells in terms of large cell lymphoma. What I would say is that anything exceeding 30%-40% at that benchmark is impressive, and I think is more than incremental. I think it's a differentiated clinical benefit.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
